ORLANDO -- First-dose reactions to IV ustekinumab (Stelara) may be related to IgE recognition of a carbohydrate allergen in patients, who may be able to tolerate subcutaneous ustekinumab instead ...

STEQEYMA is available in both subcutaneous injection and intravenous ... given the fact that Stelara ranks as one of the most expensive prescription drugs on the market," said Tom Nusbickel ...

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and ...

Otulfi in a 45 mg/0.5 mL single-dose vial for subcutaneous injection is expected to receive FDA approval in the first half of 2025. About Otulfi Otulfi (ustekinumab-aauz) is a human monoclonal ...

The human monoclonal antibody ustekinumab blocks the biologic activity of IL-12 and IL-23 by inhibiting receptors of these two cytokines on T cells, natural killer cells, and antigen-presenting cells.

The European Commission (EC) has approved ustekinumab for the treatment of moderately to severely active Crohn’s disease in paediatric patients weighing at least 40 kg. The decision follows evidence ...

STEQEYMA is available in both subcutaneous injection and intravenous infusion and ... even more Americans lower the price of their prescriptions, given the fact that Stelara ranks as one of the most ...